Cancer Treatment Centers of America And National Football League Alumni Association Work Together for Prostate Cancer

Prostate cancer is a major problem. It has been such a huge concern that the National Football League has teamed up with Cancer Treatment Centers of America in order to bring about more opportunities for screenings. This opportunity has started up in September and has gone until Oct 15. One of the issues with prostate cancer is that it affects one in seven men. Therefore, it is an huge issue, especially for men past the age of 40. There are other risk factors to look out for with prostate cancer. It is up to each individual to make sure that he is getting the regular checks so that he can avoid prostate cancer.

CTCA is one of the best facilities for getting cancer treatment. There is a ton of information available at the center that can provide people with insight on what cancer is and what they can do to maximize the effectiveness of treatment. For one thing, the current form of treatment which is chemotherapy comes with plenty of side effects since it is an antibiotic. Among the side effects are hair loss, disruptions of cognitive abilities and other side effects that could interfere with their daily lives.

One of the best things about CTCA is that they take the time to provide information on what can be done about the side effects so that people can recover better from cancer. One of the best things about getting information about cancer is that this equips people to make sure that they are able to recover in the best way. Also, the partnership of CTCA with the NFL is very helpful in that it spreads awareness of prostate cancer through one of the most enjoyed sport in America. Tons of football fans are aware of the disease and are willing to help sufferers.

Mikhail Blagoskylonny’s Accomplishments as an Oncology Expert

Mikhail Blagoskylonny is a New York-based professor of oncology who has gained global recognition due to his outstanding research in cancer and aging. The scientist has made significant discoveries that have greatly helped in improving the oncology sector. He currently does his research work at the Rosewell Park Cancer Institute and has been serving it as a professor since 2009. The scientist has also been involved in writing and publishing a couple of valuable material that focuses on aging and cancer. He is recognized for encouraging medical professionals across the globe to use Rapamycin in prolonging the lives of their patients. Blagoskylonny has gained respect in the medical research field due to his excellent knowledge of oncology.According to the scientist’s research work, Rapamycin has outstanding properties that can make it the best drug for treating cancer. The medicine is currently used for curing other life-threatening conditions that include lymphangioleiomyomatosis (LAM), hemolytic-uremic syndrome, tuberous sclerosis complex (TSC), and facial angiofibromas.

It can be accessed in pharmacies across the globe, and its local name is Rapamune. Rapamycin has been used since 1972 when it was discovered from a strain of bacteria that was on Eastern Island. It was initially used as an anti-fungal agent before professionals learned about its properties as an immunosuppressive and antiproliferative.The scientist has been acknowledged for making significant discoveries towards the development targeted cancer therapies. He has also conducted unparalleled researched on ideal cancer and anti-aging cures. Blagosklonny’ believes that cancer is related to aging since it mostly affects individuals who have passed a specific age. He is a role model to his workmates and students due to his accomplishments in the oncology sector.Blagosklonny’s career has blossomed because of his remarkable academic qualification. The professor got his Ph.D. from the First Pavlov State Medical University of St. Peterburg. He was also awarded a masters’ degree in internal medicine from the institution. The scientist’s career began in 2002 when he joined the New York Medical College to work as a researcher.

After gaining some experience, he was hired by the Ordway Research Institute to act as a senior researcher before moving to Roswell Park Cancer Institute in 2009. His role as a professor at the institute has been acknowledged since he has assisted in the invention of various targeted cancer treatments. Mikhail has also studied a lot about the aging mechanism and anti-aging drugs development. The latest research project that he is conducting is focused on discovering how aging and cancer are affected by the TOR signal.Mikhail Blagoskylonny has also established a successful career as an editor in different fields in the medical research industry. The professor has excellent knowledge of the cell cycle, aging, and oncotaget and is currently an editor-in-chief in all the areas. He has also been chosen to serve as an editor in research fields such as cancer biology and therapy. The publications that he has written are currently used by researchers and professionals who are interested in acquiring knowledge about oncology.

Why Eric Lefkofsky Is A Medical Technology Warrior

Cancer is a cruel and puzzling foe that has confounded mankind since its beginning. A disease that causes one’s body to become one’s own worst enemy, cancer seems to have any number of causes, but no apparent cures. Unless one is lucky enough to be declared cancer-free in their battle with it, the best that can be hoped for is to arrest and manage the disease with an array of powerful medications. Unfortunately some of these treatments produce serious and sometimes lethal side effects, and it’s not uncommon to hear that these treatments can be worse than the actual cancer.

Fortunately, technological advances correctly administered now mean that health care providers can create individual biological biographies and administer patient cancer care much more effectively. This is made possible in large part through the efforts of Tempus and its co-founder and CEO Eric Lefkofsky.

Tempus is computer software that allows users to map genomes and body functioning on the molecular level in real time, and use this collected data to make decisions about the best course of action involving individual patients. Tempus also delivers a complete report to physicians after patient scanning that includes current information on clinical trials that patients might qualify for, and detailed information on tumors. Tempus also can be used in conjunction with research involving animal trials to develop new types of cancer therapy.

Eric Lefkofsky is no stranger to being involved in shaking up and improving ways of doing things. In addition to his creation and involvement with Tempus, Eric did similar work in setting up Lightbank, a company that funds disruptive technologies. Disruptive technologies are ones that shake up or transform existing technologies. Next-generation genome tracking, self-driving vehicles, natural resource recovery, and cloud platform technologies are all examples of disruptive ones. And not only are these technologies disruptive, they’re transformative, meaning that they’ll impact on how these industries operate far into the future. This means that cancer patients in decades to come will benefit from the efforts of Tempus and Lefkofsky.

In addition to his Tempus and Lightbank work, Lefkofsky has co-founded Uptake, an analytical data company that provides companies with information to help improve company security and safety. In addition to focusing more recently on Tempus, Lefkofsky has become very involved recently in charitable gift giving.

In 2006, he and his wife Elizabeth founded the Lefkofsky Foundation, and since its creation, have given or pledged millions of dollars around the world, including to the Chicago public school system, and a prominent children’s hospital. He is also either a member of or sits on the board of directors of a number of cultural institutions, including the Steppenwolf Theater Company and the Chicago Institute of Art. But Lefkofsky’s touch and instincts aren’t always perfect. He also served on the committee that failed to bring the Summer Olympics to Chicago in 2016.

More information for Lefkofsky: http://www.bizjournals.com/chicago/news/2016/10/20/groupon-founder-eric-lefkofsky-joins-steppenwolf.html

Tech roundup: Lefkofsky’s Tempus comes out of stealth, AddStructure teams up with Target and more